Compare stocks

Adocia SA is a clinical-stage biotechnology company headquartered in Lyon, France, specializing in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Founded in 2005 by Gérard Soula and his sons Olivier and Rémi, the company has developed a proprietary BioChaperone® technology platform designed to enhance the efficacy and safety of therapeutic proteins. Adocia's clinical pipeline includes products such as BioChaperone Lispro, an ultra-rapid insulin formulation, and BioChaperone Combo, a combination of basal and rapid-acting insulins. The company has established a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize its products in China and other Asian and Middle Eastern territories. (,)

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.